Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations

Rita Padoan, Alessandra Bassotti, Manuela Seia, Carlo Corbetta

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Persistent hypertrypsinaemia in newborn screening for cystic fibrosis (CF) recognises subjects at high risk to be affected. Diagnosis is confirmed by a positive sweat test and/or by the presence of two mutations in the cystic fibrosis transmembrane regulator gene. The aim of the present study was to evaluate the occurrence of a negative sweat test (chloride <60 mmol/l) during the first months of life, in hypertrypsinaemic infants, which would lead to a delayed diagnosis. We reviewed clinical charts of CF patients born between January 1993 and September 1998, when the neonatal screening programme consisted of an immunoreactive trypsinogen (IRT)/DNA (F508del) + IRT strategy. Laboratory and clinical data were collected for patients diagnosed after 12 months of life. Out of 446,492 newborns, 104 CF patients were diagnosed giving an overall incidence of 1:4293. Of these, six had a blood IRT level above the cut off value (99th percentile) and a negative sweat test in the first trimester of life. At a mean age of 3.5years, the patients were again referred to our CF Centre for re-evaluation in order to confirm or exclude the disorder. Molecular analysis identified the following genotypes: F508del/A309D, F508del/3849 + 10kbC→T, F508del/R117H (in two patients), R117H/ L997F, and F508del/R117L. Conclusion: infants with cystic fibrosis bearing a spectrum of mild cystic fibrosis transmembrane regulator gene mutations may present as hypertrypsinaemic newborns with a sweat chloride within the normal range. Reference values for normal sweat test during the first months of life should be revised. A wide molecular genetic analysis is recommended for newborns presenting persistent hypertrypsinaemia and a sweat test result > 30 mmol/l in order to diagnose atypical forms of the disease.

Original languageEnglish
Pages (from-to)212-215
Number of pages4
JournalEuropean Journal of Pediatrics
Volume161
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Sweat
Cystic Fibrosis
Mutation
Regulator Genes
Chlorides
Newborn Infant

Keywords

  • CFTR gene
  • Cystic fibrosis
  • Delayed diagnosis
  • Sweat test

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. / Padoan, Rita; Bassotti, Alessandra; Seia, Manuela; Corbetta, Carlo.

In: European Journal of Pediatrics, Vol. 161, No. 4, 2002, p. 212-215.

Research output: Contribution to journalArticle

Padoan, Rita ; Bassotti, Alessandra ; Seia, Manuela ; Corbetta, Carlo. / Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. In: European Journal of Pediatrics. 2002 ; Vol. 161, No. 4. pp. 212-215.
@article{c4c76ab78485413091643772dd3e3ba8,
title = "Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations",
abstract = "Persistent hypertrypsinaemia in newborn screening for cystic fibrosis (CF) recognises subjects at high risk to be affected. Diagnosis is confirmed by a positive sweat test and/or by the presence of two mutations in the cystic fibrosis transmembrane regulator gene. The aim of the present study was to evaluate the occurrence of a negative sweat test (chloride <60 mmol/l) during the first months of life, in hypertrypsinaemic infants, which would lead to a delayed diagnosis. We reviewed clinical charts of CF patients born between January 1993 and September 1998, when the neonatal screening programme consisted of an immunoreactive trypsinogen (IRT)/DNA (F508del) + IRT strategy. Laboratory and clinical data were collected for patients diagnosed after 12 months of life. Out of 446,492 newborns, 104 CF patients were diagnosed giving an overall incidence of 1:4293. Of these, six had a blood IRT level above the cut off value (99th percentile) and a negative sweat test in the first trimester of life. At a mean age of 3.5years, the patients were again referred to our CF Centre for re-evaluation in order to confirm or exclude the disorder. Molecular analysis identified the following genotypes: F508del/A309D, F508del/3849 + 10kbC→T, F508del/R117H (in two patients), R117H/ L997F, and F508del/R117L. Conclusion: infants with cystic fibrosis bearing a spectrum of mild cystic fibrosis transmembrane regulator gene mutations may present as hypertrypsinaemic newborns with a sweat chloride within the normal range. Reference values for normal sweat test during the first months of life should be revised. A wide molecular genetic analysis is recommended for newborns presenting persistent hypertrypsinaemia and a sweat test result > 30 mmol/l in order to diagnose atypical forms of the disease.",
keywords = "CFTR gene, Cystic fibrosis, Delayed diagnosis, Sweat test",
author = "Rita Padoan and Alessandra Bassotti and Manuela Seia and Carlo Corbetta",
year = "2002",
doi = "10.1007/s00431-001-0910-8",
language = "English",
volume = "161",
pages = "212--215",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "4",

}

TY - JOUR

T1 - Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations

AU - Padoan, Rita

AU - Bassotti, Alessandra

AU - Seia, Manuela

AU - Corbetta, Carlo

PY - 2002

Y1 - 2002

N2 - Persistent hypertrypsinaemia in newborn screening for cystic fibrosis (CF) recognises subjects at high risk to be affected. Diagnosis is confirmed by a positive sweat test and/or by the presence of two mutations in the cystic fibrosis transmembrane regulator gene. The aim of the present study was to evaluate the occurrence of a negative sweat test (chloride <60 mmol/l) during the first months of life, in hypertrypsinaemic infants, which would lead to a delayed diagnosis. We reviewed clinical charts of CF patients born between January 1993 and September 1998, when the neonatal screening programme consisted of an immunoreactive trypsinogen (IRT)/DNA (F508del) + IRT strategy. Laboratory and clinical data were collected for patients diagnosed after 12 months of life. Out of 446,492 newborns, 104 CF patients were diagnosed giving an overall incidence of 1:4293. Of these, six had a blood IRT level above the cut off value (99th percentile) and a negative sweat test in the first trimester of life. At a mean age of 3.5years, the patients were again referred to our CF Centre for re-evaluation in order to confirm or exclude the disorder. Molecular analysis identified the following genotypes: F508del/A309D, F508del/3849 + 10kbC→T, F508del/R117H (in two patients), R117H/ L997F, and F508del/R117L. Conclusion: infants with cystic fibrosis bearing a spectrum of mild cystic fibrosis transmembrane regulator gene mutations may present as hypertrypsinaemic newborns with a sweat chloride within the normal range. Reference values for normal sweat test during the first months of life should be revised. A wide molecular genetic analysis is recommended for newborns presenting persistent hypertrypsinaemia and a sweat test result > 30 mmol/l in order to diagnose atypical forms of the disease.

AB - Persistent hypertrypsinaemia in newborn screening for cystic fibrosis (CF) recognises subjects at high risk to be affected. Diagnosis is confirmed by a positive sweat test and/or by the presence of two mutations in the cystic fibrosis transmembrane regulator gene. The aim of the present study was to evaluate the occurrence of a negative sweat test (chloride <60 mmol/l) during the first months of life, in hypertrypsinaemic infants, which would lead to a delayed diagnosis. We reviewed clinical charts of CF patients born between January 1993 and September 1998, when the neonatal screening programme consisted of an immunoreactive trypsinogen (IRT)/DNA (F508del) + IRT strategy. Laboratory and clinical data were collected for patients diagnosed after 12 months of life. Out of 446,492 newborns, 104 CF patients were diagnosed giving an overall incidence of 1:4293. Of these, six had a blood IRT level above the cut off value (99th percentile) and a negative sweat test in the first trimester of life. At a mean age of 3.5years, the patients were again referred to our CF Centre for re-evaluation in order to confirm or exclude the disorder. Molecular analysis identified the following genotypes: F508del/A309D, F508del/3849 + 10kbC→T, F508del/R117H (in two patients), R117H/ L997F, and F508del/R117L. Conclusion: infants with cystic fibrosis bearing a spectrum of mild cystic fibrosis transmembrane regulator gene mutations may present as hypertrypsinaemic newborns with a sweat chloride within the normal range. Reference values for normal sweat test during the first months of life should be revised. A wide molecular genetic analysis is recommended for newborns presenting persistent hypertrypsinaemia and a sweat test result > 30 mmol/l in order to diagnose atypical forms of the disease.

KW - CFTR gene

KW - Cystic fibrosis

KW - Delayed diagnosis

KW - Sweat test

UR - http://www.scopus.com/inward/record.url?scp=0036009317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036009317&partnerID=8YFLogxK

U2 - 10.1007/s00431-001-0910-8

DO - 10.1007/s00431-001-0910-8

M3 - Article

VL - 161

SP - 212

EP - 215

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 4

ER -